SCHEMBL17272791

SCHEMBL17272791

O=c1[nH]c(=S)[nH]nc1C1CC1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 3/20 0.37
▸ CYP2C9 P11712 1/20 0.36
▸ HPGD P15428 1/20 0.36
▸ GAA P10253 3/20 0.35
▸ MAPT P10636 2/20 0.35
▸ MEN1 O00255 1/20 0.35
▸ KMT2A Q03164 1/20 0.35
▸ RXFP1 Q9HBX9 4/20 0.33
▸ PPARG P37231 3/20 0.33
▸ NCOA2 Q15596 3/20 0.33
▸ NCOA1 Q15788 3/20 0.33
▸ NCOA3 Q9Y6Q9 3/20 0.33
▸ YTHDF3 Q7Z739 1/20 0.31
▸ YTHDF1 Q9BYJ9 1/20 0.31
▸ YTHDF2 Q9Y5A9 1/20 0.31
▸ KDM4E B2RXH2 1/20 0.31
▸ PKM P14618 1/20 0.31
▸ BRPF1 P55201 1/20 0.31
▸ TDP1 Q9NUW8 1/20 0.31
▸ L3MBTL1 Q9Y468 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5763194 0.92 PDE5A (0.39) ALDH1A1CYP2C9HPGDGAAMAPT
SCHEMBL13455320 0.90 PDE5A (0.41) ALDH1A1CYP2C9HPGDGAAMAPT
SCHEMBL22077239 0.83 LMNA (0.36) ALDH1A1YTHDF3YTHDF1YTHDF2PDE5A
SCHEMBL1789261 0.63 ATM (0.50) ALDH1A1GAAMAPTKDM4ENPSR1
SCHEMBL3384992 0.61 KDM3B (0.44) ALDH1A1GAAMAPTMEN1KMT2A
SCHEMBL16661295 0.61 CSNK1A1 (0.33) ALDH1A1HPGDMAPT
SCHEMBL18552741 0.61 ALDH1A1 (0.32) ALDH1A1HPGDMAPTKDM4E
SCHEMBL5793071 0.60 MAPT (0.56) ALDH1A1CYP2C9HPGDGAAMAPT
SCHEMBL11633136 0.60 ALDH1A1 (0.50) ALDH1A1CYP2C9HPGDGAAMAPT
SCHEMBL17285532 0.60 MAPT (0.40) ALDH1A1CYP2C9HPGDGAAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3661932-B1 COMPOSITIONS AND METHODS FOR STABILIZING BENZOTHIAZOLE LUCIFERIN ANALOGS PROMEGA CORP (US) 2021-10-06 — — EP claimed
US-11136615-B2 Compositions and methods for stabilizing benzothiazole luciferin analogs PROMEGA CORPORATION (US) 2021-10-05 — — US claimed
EP-3661932-A1 COMPOSITIONS AND METHODS FOR STABILIZING BENZOTHIAZOLE LUCIFERIN ANALOGS Promega Corporation (US) 2020-06-10 — — EP claimed
WO-2019028272-A1 COMPOSITIONS AND METHODS FOR STABILIZING BENZOTHIAZOLE LUCIFERIN ANALOGS PROMEGA CORPORATION (US) 2019-02-07 — — WO claimed
US-20190040449-A1 COMPOSITIONS AND METHODS FOR STABILIZING BENZOTHIAZOLE LUCIFERIN ANALOGS JPMORGAN CHASE BANK, N.A., AS COLLATERAL AGENT 2019-02-07 — — US claimed
EP-3146066-B1 COMPOSITIONS AND METHODS FOR STABILIZING LUMINOGENIC SUBSTRATES PROMEGA CORP (US) 2018-03-14 — — EP claimed
US-9676997-B2 Compositions and methods for stabilizing luminogenic substrates PROMEGA CORPORATION (US) 2017-06-13 — — US claimed
EP-3146066-A1 COMPOSITIONS AND METHODS FOR STABILIZING LUMINOGENIC SUBSTRATES Promega Corporation (US) 2017-03-29 — — EP claimed
US-20150337198-A1 COMPOSITIONS AND METHODS FOR STABILIZING LUMINOGENIC SUBSTRATES JPMORGAN CHASE BANK, N.A., AS COLLATERAL AGENT 2015-11-26 — — US claimed
WO-2015179864-A1 COMPOSITIONS AND METHODS FOR STABILIZING LUMINOGENIC SUBSTRATES PROMEGA CORPORATION (US) 2015-11-26 — — WO claimed
US-20250264464-A1 COMPOSITIONS AND METHODS FOR ANALYTE DETECTION USING BIOLUMINESCENCE PROMEGA CORPORATION 2025-08-21 — — US disclosed
EP-3661932-B1 COMPOSITIONS AND METHODS FOR STABILIZING BENZOTHIAZOLE LUCIFERIN ANALOGS PROMEGA CORP (US) 2021-10-06 — — EP disclosed
EP-3661932-B1 COMPOSITIONS AND METHODS FOR STABILIZING BENZOTHIAZOLE LUCIFERIN ANALOGS PROMEGA CORP (US) 2021-10-06 — — EP disclosed
US-11136615-B2 Compositions and methods for stabilizing benzothiazole luciferin analogs PROMEGA CORPORATION (US) 2021-10-05 — — US disclosed
US-11136615-B2 Compositions and methods for stabilizing benzothiazole luciferin analogs PROMEGA CORPORATION (US) 2021-10-05 — — US disclosed
EP-3146066-A1 COMPOSITIONS AND METHODS FOR STABILIZING LUMINOGENIC SUBSTRATES Promega Corporation (US) 2017-03-29 — — EP disclosed
WO-2015179864-A1 COMPOSITIONS AND METHODS FOR STABILIZING LUMINOGENIC SUBSTRATES PROMEGA CORPORATION (US) 2015-11-26 — — WO disclosed
WO-2015179864-A1 COMPOSITIONS AND METHODS FOR STABILIZING LUMINOGENIC SUBSTRATES PROMEGA CORPORATION (US) 2015-11-26 — — WO disclosed
US-20150337198-A1 COMPOSITIONS AND METHODS FOR STABILIZING LUMINOGENIC SUBSTRATES JPMORGAN CHASE BANK, N.A., AS COLLATERAL AGENT 2015-11-26 — — US disclosed
US-20150337198-A1 COMPOSITIONS AND METHODS FOR STABILIZING LUMINOGENIC SUBSTRATES JPMORGAN CHASE BANK, N.A., AS COLLATERAL AGENT 2015-11-26 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190040449-A1 COMPOSITIONS AND METHODS FOR STABILIZING BENZOTHIAZOLE LUCIFERIN ANALOGS TK1, TYMP, NUDT1 ALDH1A1 2006/4885CYP2C9 2452/4885HPGD 2221/4885
US-11136615-B2 Compositions and methods for stabilizing benzothiazole luciferin analogs TK1, TYMP, NUDT1 ALDH1A1 2006/4885CYP2C9 2452/4885HPGD 2221/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback